RxDoctor Payments Data

Fernando Caumont, MD

Urology · Rochester, NYNPI 1023533064

Payments from drug & device makers

$29,688in general payments, 2019–2025

Across 302 payments — averaging $98.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EDAP Technomed Inc$22K
  • Procept Biorobotics Corporation$1K
  • Johnson & Johnson$925
  • Teleflex LLC$811
  • Dendreon Pharmaceuticals LLC$411
  • Sumitomo Pharma America, Inc.$405
  • plus $4K from 32 others

What the payments were for

  • Consulting fees$12,89643%
  • Travel & lodging$8,20728%
  • Food & beverage$8,45428%
  • Education$1310%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,688 in reported general payments places this provider in the 85th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$116,796
Medicare patients
291
Services billed
2,985

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron46$23,035
GemtesaVibegron25$15,544
Mirabegron ErMirabegron16$4,126
Trospium Chloride ErTrospium Chloride20$3,525
Solifenacin Succinate64$1,660
Silodosin17$1,168
Tamsulosin Hcl161$1,100
Methenamine Hippurate27$952
Trospium Chloride11$502
Potassium Citrate ErPotassium Citrate15$487
Finasteride47$411
Oxybutynin Chloride ErOxybutynin Chloride34$393
Cephalexin28$233
Ciprofloxacin Hcl36$192
Sildenafil Citrate19$116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$331$23,03546 claims
Sumitomo Pharma America, Inc.Gemtesa$405$15,54425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 952 urology providers in New York.

Other urology in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →